Core Viewpoint - Tencent's cognitive training software "Tencent Brain Exercise" has received medical device registration approval from the Guangdong Provincial Drug Administration, marking its entry into clinical application for improving cognitive abilities in patients with mild cognitive impairment (MCI) [1][3] Industry Overview - The cognitive digital therapy market in China has over 40 companies focusing on this area, with 47 cognitive digital therapy software products approved by the National Medical Products Administration as of October 2024 [2] - The market for cognitive impairment digital therapy is expected to grow significantly, with a projected market size of 2.686 billion yuan in 2023, increasing to 10.467 billion yuan by 2025 and 89.274 billion yuan by 2030, reflecting compound annual growth rates of 97.4% and 53.5% respectively [4] - The number of MCI patients in China is approximately 38.77 million, with a prevalence rate of 15.5%, indicating a substantial patient base driving demand for cognitive digital therapies [4] Company Insights - Tencent's "Tencent Brain Exercise" transforms traditional cognitive rehabilitation into a mobile application format, utilizing gamified cognitive training based on evidence-based medicine principles [3] - The company aims to address the challenges of commercializing digital therapies, as the current business models are still in the early stages of development [1][2] - Brain Dynamics, a competitor in the market, has achieved a market share of 25.0% in the cognitive digital therapy market and 91.6% in the medical-grade cognitive digital therapy market in China, but faces challenges in profitability despite significant revenue growth [5] Challenges in the Market - The cognitive digital therapy sector is experiencing high market education costs and is still in the exploratory phase regarding application scenarios [1][2] - Regulatory challenges exist, as clinical experts have varying opinions on the clinical use of digital therapy products, which complicates their appropriate application [4][5] - The industry faces difficulties in ensuring that payers (such as insurance companies and hospitals) are willing to cover these therapies, which is crucial for sustainable business models [1][2] Competitive Landscape - Major tech companies like Tencent, Alibaba, and ByteDance are entering the healthcare sector, but a mature commercialization model is still needed [6] - The cognitive digital therapy market is characterized by a mix of substantial patient demand and ongoing challenges in commercialization pathways, creating a complex development landscape [2][4]

Core Viewpoint - Eli Lilly (LLY.US) plans to appeal the UK health authorities' decision to reject the recommendation of its new Alzheimer's drug, Kisunla, for inclusion in the public healthcare system due to cost considerations [1][2] Group 1: Regulatory Decisions - The National Institute for Health and Care Excellence (NICE) released a final draft stating that both Kisunla and Biogen's Leqembi should not be used within the National Health Service (NHS) [1] - NICE's independent expert committee concluded that the clinical benefits of these two targeted amyloid beta antibodies do not justify the additional costs to the NHS [1][2] Group 2: Company Response - Eli Lilly argues that the NICE recommendation is unfair, citing data submitted by the company, clinical experts, and patient advocacy groups [1] - The company intends to appeal the decision made by NICE regarding the inclusion of Kisunla in the NHS [1] Group 3: Approval Status - Both Leqembi and Kisunla were approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild Alzheimer's disease in adult patients in 2024 [1]

编制日经指数的《日本经济新闻》的中文版。提供日本、中国、欧美财经金融信息、商务、企业、高科技报道、评论和专栏。 以新建住宅价格除以年租金收入计算的"市盈率（PER）"，到2024年已上升至约30倍。住房PER不仅与投资相关，还是"买房还是租 房"的判断依据。例如，在PER为40倍的神田购买新房时，相当于作为初期投资要支付未来40年的租金…… 来源｜ 日经中文网（ID：rijingzhongwenwang） 封面来源 ｜ Unsplash 作为投资对象，日本东京圈的住宅正在变得"不划算"。以新建住宅价格除以年租金收入计算的"市盈率（PER）"，截至2024年已 上升至约30倍，刷新历史最高纪录，甚至超过了当前市盈率为24倍的英伟达股票。房价被推高至超出房子实际收益水平的现象， 将会持续到何时？ PER是主要在股票投资中用于判断价值高估或低估的指标。通过用企业的股价除以预期每股收益（EPS），可以求出股价是利润 水平的几倍。例如，在日本股市中，软银集团的预期PER在5月2日为23.3倍，丰田为8.0倍。英伟达由于增益与股价调整的双重影 响，在过去一年内从30倍左右降到了24.2倍。 日本不动产调查公司东京KANT ...

以下文章来源于日经中文网 ，作者日经中文网 日经中文网 . 编制日经指数的《日本经济新闻》的中文版。提供日本、中国、欧美财经金融信息、商务、企业、高科技报道、评论和专栏。 以新建住宅价格除以年租金收入计算的"市盈率（PER）"，到2024年已上升至约30倍。住房PER不仅与投资相关，还是"买房还是租 房"的判断依据。例如，在PER为40倍的神田购买新房时，相当于作为初期投资要支付未来40年的租金…… 来源｜ 日经中文网（ID：rijingzhongwenwang） 封面来源 ｜ Unsplash 作为投资对象，日本东京圈的住宅正在变得"不划算"。以新建住宅价格除以年租金收入计算的"市盈率（PER）"，截至2024年已 上升至约30倍，刷新历史最高纪录，甚至超过了当前市盈率为24倍的英伟达股票。房价被推高至超出房子实际收益水平的现象， 将会持续到何时？ PER是主要在股票投资中用于判断价值高估或低估的指标。通过用企业的股价除以预期每股收益（EPS），可以求出股价是利润 水平的几倍。例如，在日本股市中，软银集团的预期PER在5月2日为23.3倍，丰田为8.0倍。英伟达由于增益与股价调整的双重影 响，在过去一年内从 ...

Core Viewpoint - The news highlights the supply issues surrounding GV-971 (甘露特钠胶囊), a drug for Alzheimer's disease, which has led to a significant price increase and potential production halt due to regulatory challenges and cash flow problems faced by the manufacturer,绿谷制药 [1][3][5]. Group 1: Supply and Demand - GV-971 has been experiencing a supply shortage since six months ago, with recent reports indicating complete stockouts, causing prices to surge from 296 yuan to between 830 yuan and 1,033 yuan per box [1]. - Over 9,300 patients have requested the drug, and more than 1,200 doctors have urged the company to ensure continuous supply [1]. - The company is in communication with relevant authorities to expedite the review process for the drug's certification renewal [1][2]. Group 2: Regulatory and Clinical Background - GV-971 was conditionally approved in November 2019, becoming the first drug targeting the "gut-brain axis" mechanism for Alzheimer's treatment [3]. - The drug's approval was contingent upon the submission of long-term carcinogenicity data, which was completed and submitted in December 2019, showing no carcinogenic risk [3]. - The drug has been under review since October 2024, but its approval status remains pending, possibly due to ongoing debates regarding its efficacy [4]. Group 3: Financial Performance and Market Impact - Since its launch, GV-971 has reportedly benefited over 500,000 patients, with sales reaching 2.13 million boxes in 2024 alone [5]. - The drug's sales have grown at a compound annual growth rate of 343.2% since its approval, with hospital sales reaching 170 million yuan and retail sales at 156 million yuan in 2022 [5]. - The company has faced severe cash flow issues, leading to temporary layoffs and reduced salaries for employees [2]. Group 4: Alternative Treatments and Market Landscape - Despite the supply issues with GV-971, other established treatments for Alzheimer's disease, such as cholinesterase inhibitors and NMDA receptor antagonists, remain available [6]. - Newer drugs like Eli Lilly's donanemab and Eisai's lecanemab have also entered the market, providing additional options for patients [7]. - The Alzheimer's drug development landscape is characterized by high investment and risk, with over $100 billion invested globally, yet only one drug successfully launched from over 200 clinical trials [8][9].

Core Viewpoint - The production of the Alzheimer's drug "Jiuyiqi" by Green Valley Pharmaceutical has been halted due to the expiration of its license, prompting concerns among patients about when it will resume production. The drug is required to supplement its Phase III clinical data, which has been deemed insufficient [1][2]. Group 1: Clinical Trial and Regulatory Issues - The initial Phase III clinical trial for "Jiuyiqi" was conducted over a period of only 9 months, which has raised significant concerns regarding its adequacy compared to international standards that typically require two parallel trials [1][2]. - The drug was conditionally approved in November 2019, with the understanding that additional data, including a long-term carcinogenicity study in rats, would be submitted within three months. This data has since been provided, showing no carcinogenic risk [2]. - Due to the COVID-19 pandemic, the originally planned global clinical trials were reduced to a smaller scale conducted domestically, which has led to questions about the rigor of the trial design [3]. Group 2: Market Context and Competitive Landscape - Since the launch of "Jiuyiqi," it has been included in the medical insurance system, significantly reducing the monthly treatment cost from over 1500 RMB to under 300 RMB [4]. - In the past year, new Alzheimer's treatments such as Lecanemab and Donanemab have been approved, but they come with high annual treatment costs of around 200,000 RMB and are not yet covered by insurance [4]. - There is a strong call within the industry for domestic manufacturers to continue investing in innovative Alzheimer's drug development to address the substantial unmet clinical needs, as existing treatments are either expensive or ineffective for late-stage diseases [4].

Core Viewpoint - The prescription drug GV-971 (brand name "Jiuyiqi") for Alzheimer's disease has been discontinued, leading to a significant price increase and supply shortages, raising concerns about the company's future and the drug's efficacy [1][3][4]. Group 1: Company Situation - Green Valley Pharmaceutical Technology is facing severe cash flow issues, having notified all employees of a three-month leave starting in June, with salaries reduced to 2,600 yuan per month [3][4]. - The company has indicated that the drug's production halt is due to the expiration of its drug registration certificate, with new approvals pending [5][6]. - There have been over 9,300 patient requests for the drug, and more than 1,200 doctors have urged the company to ensure the supply of GV-971 [6][7]. Group 2: Drug Efficacy and Controversy - GV-971 has been subject to academic controversy, with former president of Capital Medical University, Rao Yi, questioning the authenticity of the research and the drug's effectiveness, alleging research misconduct [4][8]. - The drug was conditionally approved by the National Medical Products Administration in November 2019, and it was included in the medical insurance list in 2021 at a price of 296 yuan per box [4][7]. - Despite the controversies, the company claims that the drug has shown improvements in cognitive function in patients during clinical studies, with results expected to be presented at international academic conferences [7][10]. Group 3: Market Dynamics - The price of GV-971 has surged to between 830 yuan and 1,033 yuan per box due to supply shortages, compared to its original price of 296 yuan [1][4]. - The drug has sold 2.13 million boxes in 2024 alone, indicating a significant market presence despite the ongoing controversies [4][11]. - The approval process for new drugs in the Alzheimer's treatment space is generally slow, with industry insiders suggesting that the ongoing efficacy debates may be contributing to the delays in GV-971's new registration [6][8].

Investment Rating - The report indicates a positive investment rating for the innovative drug sector, particularly highlighting the success of the combination therapy of Bemesumab and Anlotinib in treating NSCLC [8][11]. Core Insights - The report emphasizes the significant progress in the treatment of non-small cell lung cancer (NSCLC) through innovative therapies, particularly the combination of immune checkpoint inhibitors and anti-angiogenic agents, which have shown improved progression-free survival (PFS) rates compared to traditional therapies [7][11]. - The CAMPASS trial demonstrated that the combination of Bemesumab and Anlotinib significantly extended the median PFS to 11.0 months compared to 7.1 months for the control group, marking a notable advancement in first-line treatment options for PD-L1 positive advanced NSCLC [11]. - The report also discusses the ongoing clinical trials and the potential for new drug approvals, indicating a robust pipeline for innovative therapies in the oncology sector [12][47]. Summary by Sections Section 1: Focus on Innovative Drugs - The report reviews the latest developments in innovative drugs, particularly in the context of NSCLC treatments and highlights the importance of combination therapies [2][3]. Section 2: Clinical Trial Results - The report details the results of the CAMPASS trial, which compared the efficacy of Bemesumab combined with Anlotinib against Pembrolizumab in treating advanced NSCLC, showcasing a significant improvement in PFS [11][12]. - It also covers the mid-term analysis of the TQB2450-III-12 trial, which further supports the efficacy of the Bemesumab and Anlotinib combination in squamous NSCLC [13]. Section 3: Market Developments - The report notes the recent approvals and submissions for new drug indications, reflecting a dynamic and rapidly evolving market for innovative cancer therapies [45][49]. - It highlights the performance of various biotech companies in the market, indicating significant fluctuations in stock prices and market capitalization [41][43].

Group 1: Company News - Paige Biopharma officially listed on the Hong Kong Stock Exchange with an initial price of HKD 15.6, but saw a first-day drop of 25.9%, closing at HKD 11.66, resulting in a market capitalization of approximately HKD 32.55 billion. The company focuses on innovative therapies for chronic diseases, particularly in the endocrine and metabolic fields, with six candidate products but no commercialized products yet. The most advanced product, PB-119, is a GLP-1 agonist for diabetes, with registration applications submitted for both monotherapy and combination therapy [1] - Eisai's new drug, lemborexant (brand name: Dayvigo), has been approved for sale in China for the treatment of insomnia. This drug is a dual orexin receptor antagonist that improves sleep quality by regulating the orexin system. It is the first of its kind approved in China, with several other similar products also in the pipeline [2] - Xiantong Pharmaceutical submitted its listing application to the Hong Kong Stock Exchange, with a focus on oncology, neurodegenerative diseases, and cardiovascular diseases. The company reported revenues of approximately CNY 10.23 million and CNY 44.06 million for 2023 and 2024, respectively, with corresponding losses of approximately CNY 309 million and CNY 156 million [4] Group 2: Industry News - Hainan Provincial People's Hospital was fined CNY 15.06 million for violating medical insurance fund regulations, including excessive examinations and improper billing practices. This highlights the need for stricter regulation of medical insurance funds to protect public resources [3] - Multiple regions, including Jiangxi and Anhui, have initiated comprehensive investigations into past violations in medical insurance enforcement, focusing on issues such as arbitrary charges and excessive inspections. This effort aims to standardize medical insurance enforcement and promote a more regulated industry environment [5]

Group 1 - The newly approved drug, Lemborexant (brand name: Dazavt), is a novel insomnia therapy that works by inhibiting the wake-promoting effects of orexin, differing from traditional medications [1] - Lemborexant is a dual orexin receptor antagonist that targets both OX1R and OX2R receptors, allowing for precise regulation of the orexin system [1] - The drug has been approved for the treatment of adult insomnia, particularly for those with difficulties in falling asleep and/or maintaining sleep [1] Group 2 - Professor Chen Jun from Shanghai Mental Health Center highlighted that the mechanism of this new drug represents an innovation compared to traditional benzodiazepines, which have safety concerns [3] - Traditional benzodiazepines can lead to addiction, tolerance, and various side effects, including cognitive impairment and dependence [3] - Lemborexant has been included in the "Guidelines for the Diagnosis and Treatment of Insomnia in Adults (2023 Edition)" as an IA-level recommended drug [3] Group 3 - The first step in standardized treatment for insomnia is not medication, but rather the adjustment of healthy sleep habits and psychological therapy, with medication considered only if these methods are ineffective [4]